JP2023530154A - 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート - Google Patents

赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート Download PDF

Info

Publication number
JP2023530154A
JP2023530154A JP2022577503A JP2022577503A JP2023530154A JP 2023530154 A JP2023530154 A JP 2023530154A JP 2022577503 A JP2022577503 A JP 2022577503A JP 2022577503 A JP2022577503 A JP 2022577503A JP 2023530154 A JP2023530154 A JP 2023530154A
Authority
JP
Japan
Prior art keywords
polysaccharide
flexneri
protein
epa
glycosylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530154A5 (https=
JPWO2021255684A5 (https=
Inventor
エドワード ブラウン，マーティン
フォラドール，ライナー
ヨッヘン ケムラー，シュテファン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2023530154A publication Critical patent/JP2023530154A/ja
Publication of JP2023530154A5 publication Critical patent/JP2023530154A5/ja
Publication of JPWO2021255684A5 publication Critical patent/JPWO2021255684A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022577503A 2020-06-18 2021-06-17 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート Pending JP2023530154A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063040844P 2020-06-18 2020-06-18
US63/040,844 2020-06-18
US202063043883P 2020-06-25 2020-06-25
EP20182138.6 2020-06-25
EP20182138 2020-06-25
US63/043,883 2020-06-25
EP20182139.4 2020-06-25
EP20182139 2020-06-25
PCT/IB2021/055361 WO2021255684A1 (en) 2020-06-18 2021-06-17 Shigella-tetravalent (shigella4v) bioconjugate

Publications (3)

Publication Number Publication Date
JP2023530154A true JP2023530154A (ja) 2023-07-13
JP2023530154A5 JP2023530154A5 (https=) 2024-06-20
JPWO2021255684A5 JPWO2021255684A5 (https=) 2024-06-20

Family

ID=76502778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577503A Pending JP2023530154A (ja) 2020-06-18 2021-06-17 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート

Country Status (8)

Country Link
US (1) US20230346902A1 (https=)
EP (1) EP4168040A1 (https=)
JP (1) JP2023530154A (https=)
CN (1) CN115697396A (https=)
BR (1) BR112022024294A2 (https=)
CA (1) CA3185719A1 (https=)
MX (1) MX2022016587A (https=)
WO (1) WO2021255684A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514155A (ja) * 2008-02-20 2011-05-06 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
JP2015533497A (ja) * 2012-10-12 2015-11-26 グリコヴァキシン アーゲー 宿主細胞改変方法
JP2015533511A (ja) * 2012-11-07 2015-11-26 グリコヴァキシン アーゲー 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造
JP2018517729A (ja) * 2015-06-16 2018-07-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR20090110951A (ko) 2002-03-07 2009-10-23 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2671709C (en) 2006-12-13 2016-08-16 The Governors Of The University Of Alberta Methods and systems for o-glycosylating proteins
EP2501406B8 (en) 2009-11-19 2018-01-24 GlaxoSmithKline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514155A (ja) * 2008-02-20 2011-05-06 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
JP2015533497A (ja) * 2012-10-12 2015-11-26 グリコヴァキシン アーゲー 宿主細胞改変方法
JP2015533511A (ja) * 2012-11-07 2015-11-26 グリコヴァキシン アーゲー 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造
JP2018517729A (ja) * 2015-06-16 2018-07-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICAL INFECTIOUS DISEASE, vol. Vol. 59, Issue 7, JPN6025016425, 2014, pages 933 - 941, ISSN: 0005792928 *
INFECTION AND IMMUNITY, vol. 61, JPN6026005106, 1993, pages 3678 - 3687, ISSN: 0005792931 *
MBIO, vol. vol.7, issue 2, JPN6025016426, 2016, pages 00443 - 16, ISSN: 0005587516 *
NPJ VACCINES, vol. 4, JPN6026005107, 2019, pages 16, ISSN: 0005792932 *
THE LANCET, vol. 349, JPN6026005103, 1997, pages 155 - 159, ISSN: 0005792930 *

Also Published As

Publication number Publication date
WO2021255684A1 (en) 2021-12-23
EP4168040A1 (en) 2023-04-26
CN115697396A (zh) 2023-02-03
BR112022024294A2 (pt) 2023-02-28
CA3185719A1 (en) 2021-12-23
MX2022016587A (es) 2023-02-01
US20230346902A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CN106535927B (zh) 新颖多糖及其用途
JP7551618B2 (ja) Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
EP2142660B1 (en) Methods and systems for o-glycosylating proteins
JP7589164B2 (ja) 大腸菌ｏ抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法
US20230293657A1 (en) Vaccine
US20140336366A1 (en) Bioconjugate vaccines made in prokaryotic cells
KR20230164108A (ko) E. coli O18 생물접합체의 생산
JP2022541911A (ja) バイオコンジュゲートグリコシル化の定量化
JP2023530154A (ja) 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート
EP1747262B1 (en) Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
Castro et al. A platform for the recombinant production of Group A Streptococcus glycoconjugate vaccines
US20250381257A1 (en) Vaccine
JP2025535072A (ja) モラクセラ科ｏ結合型オリゴ糖転移酵素、糖鎖付加断片、及びそれらの使用
Dawson Streptococcus equi polysaccharide vaccine target for Strangles disease: A potential model for Group A Streptococcal human vaccines
CN121693343A (zh) 经修饰的蛋白质
WO2024175620A1 (en) Immunogenic composition
KR20260051063A (ko) 변형된 단백질
Donaldson Antimicrobial Carbohydrate Vaccines: Development of Burkholderia pseudomallei immunogens
PL229194B1 (pl) Neoglikokoniugat oligocukru Escherichia coli R1 LOS i toksoidu Clostridium difficile oraz jego zastosowanie w szczepionkach przeciwbakteryjnych

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210